Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (361-370 of 394) with videos related to

Pageof 40
Sort By:
Nature Reviews. Rheumatology|January 26, 2026
Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trialsGrace Lu, Tyler Cepica, Catherine Barbey, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JACC. Cardiovascular Imaging|March 21, 2021
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory DisordersBrittany N Weber, Emma Stevens, Lourdes M Perez-Chada, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
Cardiovascular Research|January 16, 2026
Inflammatory risk quantification in systemic inflammatory disease using coronary CT angiographyBrittany Weber, Christos P Kotanidis, Daniel M Huck, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Pageof 40

Showing results (361-370 of 394) with videos related to

Sort By:
Pageof 40
Nature Reviews. Rheumatology|January 26, 2026
Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trialsGrace Lu, Tyler Cepica, Catherine Barbey, et al.
Annals of the Rheumatic Diseases|June 19, 2025
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414Christopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.
Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.
RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.
JACC. Cardiovascular Imaging|March 21, 2021
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory DisordersBrittany N Weber, Emma Stevens, Lourdes M Perez-Chada, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.
The Journal of Rheumatology|July 7, 2023
Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working GroupYing-Ying Leung, William Tillett, Maarten de Wit, et al.
Cardiovascular Research|January 16, 2026
Inflammatory risk quantification in systemic inflammatory disease using coronary CT angiographyBrittany Weber, Christos P Kotanidis, Daniel M Huck, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Dermatology (Basel, Switzerland)|September 19, 2021
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual MeetingAlison H Kohn, Afsaneh Alavi, April W Armstrong, et al.
Pageof 40